Aytu BioPharma Inc. (NASDAQ:AYTU) Stock Now Rated “Hold” by Sell-Side Brokerages

Aytu BioPharma Inc. (NASDAQ:AYTU) has received a consensus recommendation of “Hold” from the four ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $14.50.

AYTU has been the subject of a number of research analyst reports. Citigroup reaffirmed a “positive” rating on shares of Aytu BioPharma in a research note on Tuesday, September 22nd. Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Ascendiant Capital Markets increased their price target on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research note on Thursday, June 11th. Finally, Weiss Ratings raised Aytu BioPharma from a “sell (d-)” rating to a “sell (d)” rating in a research note on Tuesday, September 22nd.

Aytu BioPharma Stock Down 4.8%

Shares of Aytu BioPharma stock opened at $2.17 on Tuesday. The stock has a market capitalization of $23.59 million, a price-to-earnings ratio of -1.31 and a beta of 0.26. Aytu BioPharma has a twelve month low of $1.65 and a twelve month high of $3.07. The company has a current ratio of 1.13, a quick ratio of 1.00 and a debt-to-equity ratio of 0.26. The business’s 50 day simple moving average is $2.22 and its 200-day simple moving average is $2.32.

Hedge Funds Weigh In On Aytu BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Aytu BioPharma during the 2nd quarter worth approximately $49,000. Persistent Asset Partners Ltd purchased a new stake in Aytu BioPharma in the 2nd quarter worth about $82,000. Dimensional Fund Advisors LP lifted its stake in Aytu BioPharma by 23.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after acquiring an additional 8,222 shares in the last quarter. Arete Wealth Advisors LLC acquired a new stake in Aytu BioPharma during the 1st quarter worth about $135,000. Finally, Crown Advisors Management Inc. purchased a new position in Aytu BioPharma during the 2nd quarter valued at about $430,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.